Funding Daily Summary
Funding Daily Summary: What Happened on October 4, 2026
Ai3Bio raises $48 million for immune-reset therapies
The startup’s first approach targets inflammatory T cells, with initial human tests possible next year.
Today in brief
Ai3Bio emerged from stealth with a $48 million Series A to advance its immune-reset therapy pipeline.1 Its first intended target is Th17 cells, and initial human tests could begin next year.1
Also worth knowing
-
Ai3Bio’s antibody-guided lipid nanoparticles are designed to carry mRNA into target cells and activate the cGAS-STING pathway. Co-founder Jonathan Kagan said animal studies depleted inflammatory T cells, including in monkeys’ spleens and lymph nodes, but durability has not been demonstrated in people.1